A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Clinical Sarcoma Research Pub Date : 2019-09-11 DOI:10.1186/s13569-019-0122-5

N. Bui, J. Przybyl, S. Trabucco, G. Frampton, T. Hastie, M. van de Rijn, K. Ganjoo

引用次数: 43

查看原文本刊更多论文

软组织肉瘤患者的临床基因组分析显示CDKN2A缺失是预后不良的生物标志物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Sarcoma Research

自引率

0.00%

发文量

期刊介绍： Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.